Drugs / OT-551
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00485394 | Jun 2007 → Feb 2010 | age-related macular degeneration | Othera Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT00306488 | Mar 2006 → Mar 2010 | age-related macular degeneration, diffuse secondary choroid atrophy | National Institutes of Health Clinical Center (CC) | Completed | Met primary |
| Phase 2 | NCT00333060 | Nov 2005 → Jan 2008 | macular holes, preretinal fibrosis | Othera Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OT-551 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00306488 ↗ |
| Modality | Small molecule | “OT-551, a disubstituted hydroxylamine with antioxidant properties” PMID 20574018 ↗ Jun 2010 |
| Route | Topical | “Topical 0.45% OT-551 was administered in one randomly assigned eye three times daily for 2 years.” PMID 20574018 ↗ Jun 2010 |